The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
Abstract
Authors
M. Charokopou P. McEwan S. Lister L. Callan K. Bergenheim K. Tolley M. Roudaut